Significance of atypical urinary cytology in the evaluation of patients with end-stage renal disease for kidney transplantation - a retrospective study.
atypical cytology
renal transplantation
urothelial carcinoma
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
14
10
2018
revised:
03
01
2019
accepted:
13
05
2019
pubmed:
18
5
2019
medline:
14
3
2020
entrez:
18
5
2019
Statut:
ppublish
Résumé
To determine what percentage of renal transplant candidates have atypical urinary cytology, what proportion have urothelial carcinoma and whether cystoscopy is necessary with atypical cytology. All end-stage renal disease (ESRD) patients (703) presenting for renal transplantation at our institution were retrospectively reviewed. Individuals producing sufficient urine were screened with urine cytology and those with atypical cytology or risk factors for bladder cancer underwent cystoscopy. Four hundred and thirty patients had available urinary cytology and, of these, 151 (35%) had atypical cytology. Of patients with atypical cytology, three were identified to have urothelial carcinoma. However, three additional patients with urothelial carcinoma did not present with atypical cytology. In total, 6 of 703 (0.85%) patients had bladder cancer. All were treated with transurethral resection and eventually underwent renal transplant. One patient has had disease progression post-transplant to distant metastases. This is the largest study to date evaluating the incidence of urothelial carcinoma in ESRD patients presenting for transplant workup. We found the incidence of bladder cancer to be higher than in the general Canadian population, however, most lesions were low grade. We found atypical cytology in transplant candidates to be a poor predictor for these low-grade lesions and do not recommend routine cystoscopy for atypical cytology.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1085-1094Informations de copyright
© 2019 Steunstichting ESOT.
Références
Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ. Impact of renal cadaveric transplantation on survival in end-stage renal failure: evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 1998; 9: 2135.
Port FK, Wolfe RA, Mauger EA, Berling DPJK. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339.
Ojo AO, Port FK, Wolfe RA, Mauger EA, Williams LBD. Comparative mortality risks of chronic dialysis and cadaveric transplantation in black end-stage renal disease patients. Am J Kidney Dis 1994; 24: 59.
Kälble T, Lucan M, Nicita G, Sells R, Revilla FJB, Wiesel M. Eau guidelines on renal transplantation. Eur Urol 2005; 47: 156.
Chapman JR, Baan CC, Bromberg JS, et al. KDIGO clinical practice guideline on the evaluation and care of living kidney donors. Transplantation 2017; 101: 8S.
Trillium Gift of Life Network. Ontario's Referral and Listing Criteria for Adult Kidney Transplantation. 1-4.
Transplant B. Clinical Guidelines for Kidney Transplantation, 2017: 1-66.
Knoll G, Cockfield S, Blydt-hansen T, Baran D, Kiberd B, Landsberg D. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173: S1-25.
Barkan GA, Wojcik EM, Nayar R, et al. The Paris system for reporting urinary cytology: the quest to develop a standardized terminology. Acta Cytol 2016; 60: 185.
Jankovi S, Radosavljevi V. Risk factors for bladder cancer. Tumori 2007; 93: 4.
Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93.
Holley JL. Cancer screening in ESRD. J Am Soc Nephrol 2016; Chapter 17: 1.
Morton J, Howe S, Lowell J, Stratta R, Taylor R. Influence of end stage renal disease and renal transplantation on serum prostate specific antigen. Br J Urol 1995; 75: 498.
Remzi M, Kovarik J, Hoerl WH, Marberger M. CME Article Impact of Chronic Dialysis on Serum PSA, Free PSA, and Free/Total PSA Ratio : Is Prostate Cancer, 1979; 4295.
De Sala O'Shea E, Morey Molina A, Ferrutxe Frau J, Gutiérrez Sanz-Gadea C, Alarcon Zurita AOMM. Cancer of the bladder and hemodialysis. Arch Esp Urol 1990; 43: 359.
Pecqueux J, Schwarz A, Dieckmann K, Offermann G. Cancer incidence in patients on chronic dialysis and in renal transplant recipients. Urol Int 1990; 45: 290.
Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017. Available at https://cancer.ca/Canadian-Cancer-Statistics-2017-EN
Jiaan B, Yu C, Lee Y, Huang J. Uraemia with concomitant urothelial cancer. Br J Urol 1993; 72: 458.
Chen K, Lai M, Huang C, Chu S, Leuk M. Urologic cancer in uremic patients. Am J Kidney Dis 1995; 25: 694.
Ou J, Pan C, Lin J, Tzai T. Transitional cell carcinoma in dialysis patients. Eur Urol 2000; 37: 90.
Wang H, Hsieh H, Chen Y, Chiang C, Cheng Y. The outcome of post-transplant transitional cell carcinoma in 10 renal transplant recipients. Clin Transpl 2002; 16: 410.
Wu M, Lian J, Yang C, Cheng C. High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan. Am J Kidney Dis 2004; 43: 1091.
Sullivan PS, Chan JB, Levin MR, Rao J. Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res 2010; 2: 412.
Bastacky S, Ibrahim S, Wilczynski SPMW. The accuracy of urinary cytology in daily practice. Cancer 1999; 87: 118.
Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR. Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol 2007; 127: 946.
Mokhtar GA, Al-Dousari M, Al-Ghamedi D. Diagnostic significance of atypical category in the voided urine samples: a retrospective study in a tertiary care center. Urol Ann 2010; 2: 100.
Brimo F, Vollmer RT, Case B, Aprikian A, Kassouf W, Auger M. Accuracy of urine cytology and the significance of an atypical category. Am J Clin Pathol 2009; 132: 785.
Chau K, Rosen L, Coutsouvelis C, et al. Accuracy and risk of malignancy for diagnostic categories in urine cytology at a large tertiary institution. Cancer Cytopathol 2015; 123: 10.
Ubago JM, Mehta V, Wojcik EM, Barkan GA. Evaluation of atypical urine cytology progression to malignancy. Cancer Cytopathol 2013; 121: 387.
Veltman G, Bosch F, van der Plas-Cats M, van Leusen R. Urine cytology as a screening method for transitional-cell carcinoma in dialysis patients with analgesic nephropathy. Nephrol Dial Transplant 1991; 6: 346.
Hadatsuki H, Sasagawa I, Suzuki H, Yaguchi H, Mutoh A, Kubota YNT. Bladder cancer in a patient on long-term haemodialysis. Int Urol Nephrol 1998; 30: 565.
Bhatia A, Dey P, Kakkar N, Srinivasan R, Nijhawan R. Malignant atypical cell in urine cytology: a diagnostic dilemma. Cytojournal 2006; 3: 28.
Sato Y, Kondo T, Takagi T, Junpei I, Tanabe K. Treatment strategy for bladder cancer in patients on hemodialysis: a clinical review of 28 cases. Int Urol Nephrol 2016; 48: 503.
Yossepowitch O, Sagy I, Margel D, Baniel J. Urothelial carcinoma of the bladder in patients on hemodialysis: clinical characteristics and oncological outcomes. J Urol 2012; 187: 1215.
Wu C, Shee J, Ho D, Chen W, Chen C. Different treatment strategies for end stage renal disease in patients with transitional cell carcinoma. J Urol 2004; 171: 126.
Matson MA, Cohen EP. Acquired cystic kidney disease: occurrence, prevalence, and renal cancers. Medicine (Baltimore) 1990; 69: 217.
Merchen T, Gupta M, Hanaway M. Pre-existing bladder cancer in solid organ transplant recipients (abstract 757). Am J Transpl 2003; 3: 346.
Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000; 7: 147.
Kasiske B, Cangro C, Hariharan S, et al. The evaluation of renal transplant candidates: clinical practice guidelines. Am J Transpl 2001; 2: 95.
Sun H, Singh N. Should intravesical Bacillus Calmette-Guérin be employed in transplant recipients with bladder carcinoma? Transpl Infect Dis 2010; 12: 358.
Sokolova IA, Halling KC, Jenkins RB, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in Urine. J Mol Diagnostics 2000; 2: 116.